Freenome Inc is a development-stage, early cancer detection company developing blood-based screening tests leveraging a proprietary artificial intelligence/machine learning multiomics technology platform to transform multi-cancer and ultimately multi-disease detection. It is developing a range of blood-based cancer screening tests.
Last trade$9.98
Day change-$0.115 (-1.14%)
Day range$9.83 – $10.80
Volume287,556
Market cap$1.13B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$1.13B
Price / earnings
19×
Price / book
2.34×
Price / sales
6.13×
EV / sales
5.15×
EV / EBITDA
11.14×
Profitability
Earnings per share
$0.53
Return on assets
8.07%
Return on equity
12.3%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
12.73×
Quick ratio
12.68×
Cash ratio
4.98×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$74.26M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for FRNM, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Revenue
$183.49M
Cost of revenue
$478K
Gross profit
$183.01M
Selling, general and administrative
$44.63M
Research and development
$68.42M
Total operating expenses
$113.05M
Operating income
$69.97M
Interest expense
-$1.19M
Income before taxes
$60.11M
Income taxes
$0
Net income
$60.11M
Net income attributable to common shareholders
$60.11M
EBITDA
$88.26M
Basic earnings per share
$0.60
Diluted earnings per share
$0.58
Recent news
Company coverage with links to the original publishers.
Freenome announced improved validation data for its updated SimpleScreen CRC blood-based colorectal cancer screening test, demonstrating 18.2% sensitivity for advanced precancerous lesions (up from 13.7%) and 80.4% sensitivity for colorectal cancer detection at 90% specificity. The FDA-approved test, commercialized by partner Abbott Cancer Diagnostics, will be presented at ACG 2026 Annual Meeting in Nashville.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.